Tyler D., Hundertmark M., Siu A., Matthews V., Lewis A., Grist J., Patel J., Chamberlin P., Sarwar R., Yavari A., Dehbi H-M., Frenneaux M., Valkovič L., Miller J., Neubauer S., Rider O.

Patients with Type 2 Diabetes (T2D) are at a significantly increased risk of heart failure (HF) with the development of HF driven by energetic, metabolic, structural, and functional cardiac changes. In this study we have used a multi-nuclear MRI/MRS approach to demonstrate that the novel metabolic modulator, ninerafaxstat, can significantly improve myocardial energetics, cardiac steatosis and diastolic function in patients with T2D and obesity. In addition, using cardiac hyperpolarized [1-13C]pyruvate MRS, we have identified a potential signal for increased pyruvate dehydrogenase flux upon treatment with ninerafaxstat.

Multi-Nuclear MRI/MRS Study Exploring the Impact of a Novel Cardiac Mitotrope in the Treatment of Diabetic Cardiomyopathy

Tyler D., Hundertmark M., Siu A., Matthews V., Lewis A., Grist J., Patel J., Chamberlin P., Sarwar R., Yavari A., Dehbi H-M., Frenneaux M., Valkovič L., Miller J., Neubauer S., Rider O.

DOI

Type

Publisher

Publication Date